Oligonucleotide Therapeutics Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Canada, UK, Germany, Japan - Size and Forecast 2024-2028

Oligonucleotide Therapeutics Market Size 2024-2028

The global oligonucleotide therapeutics market size is estimated to grow by USD 13.44 billion, at a CAGR of 19.87% between 2022 and 2027. 

The rising elderly population faces a heightened risk of neurological disorders, with Parkinson's disease and Alzheimer's disease being prevalent. Neurological conditions afflict one in three individuals globally, according to the Lancet, posing significant challenges as the leading cause of illness and disability worldwide. Age-related degeneration increases vulnerability to nerve deterioration, amplifying the incidence of neurodegenerative disorders like Alzheimer's. Consequently, conventional treatments' limitations have spurred research into alternative therapies, including oligonucleotide therapeutics. Notably, compounds like LMTX, targeting tau protein, hold promise in enhancing cognitive function for Alzheimer's patients. The escalating incidence and prevalence of neurological disorders, coupled with the growing demand for effective treatments to mitigate patient suffering, are anticipated to drive market growth in the forecast period. As the elderly population expands and neurological conditions become increasingly prevalent, the need for innovative therapies like oligonucleotide therapeutics grows, presenting opportunities for market advancement.

What will be the Size of the Market During the Forecast Period?

To learn more about this report, Download Report Sample

Segmentation by Type, Application and Geography Analysis

Type Analysis

The market share growth by the antisense oligonucleotides segment will be significant during the forecast period. The Antisense technology field, encompassing Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory, RNAi, and other nucleotide-based medications, has gained significant traction in healthcare due to its potential in treating various diseases. These advanced RNA-based therapeutic techniques, including Antisense RNA, RNA vaccines, and CRISPR-Cas9, are increasingly being explored for infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, kidney diseases, and neuromuscular diseases.

Get a glance at the market contribution of various segments Download PDF Sample

The antisense oligonucleotides were the largest segment and were valued at USD 1.89 billion in 2018. The shift towards precision medicine and personalized therapies has fueled the demand for these targeted treatments, which can detect minor genetic mutations or disease targets with minimal off-target effects. The expanding pipeline of pharmaceutical research in this area, driven by biomedical science and genetic testing, is expected to significantly impact healthcare expenditure and improve lifeline curves for patients with genes associated with disorders. Key therapeutic applications include cancer, RNA, DNA, and RNAi treatments for biological processes. Pharmaceutical firms and biotechnology companies are investing heavily in this field to develop novel therapies for various diseases.

Application Analysis

In neurological disorders, oligonucleotides are used to regulate gene expression and modulate alternative splicing patterns. They target disease-associated genes involved in neurodegeneration and are employed in splice-switching therapies to correct splicing defects. RNAi-based approaches, including siRNAs and microRNA inhibitors, silence disease-related genes implicated in neurodegenerative diseases. Oligonucleotides also play a vital role in biomarker discovery for neurological disorders, facilitating early diagnosis and treatment monitoring. Notably, companies like Ionis Pharmaceuticals Inc. offer ASOs for diseases such as Huntington's disease and spinal muscular atrophy, contributing to the growth of the neurological segment in the oligonucleotide therapeutics market.

Oligonucleotides play a crucial role in targeted cancer therapies, offering precise and personalized treatments by specifically targeting cancer-related genes. They are utilized in gene expression profiling to analyze changes associated with cancer development and treatment response. Additionally, oligonucleotides aid in identifying biomarkers for cancer diagnosis and prognosis, contributing to the development of sensitive detection assays. Furthermore, they are integral to cancer immunotherapies, modulating immune responses and enhancing anti-tumor immunity. The development of novel RNAi therapeutics, exemplified by Alnylam Pharmaceuticals Inc.'s Onpattro, ATTR further drives growth in the cancer segment of the market.

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 39% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional market trends and drivers that will shape the market during the forecast period. The North American market for oligonucleotide therapeutics holds significant potential, primarily due to the advanced healthcare infrastructure in countries like the US and Canada. These nations bear a substantial disease burden and are major contributors to the region's market growth. The US, in particular, is a significant driver, with its substantial investments in healthcare research and institutions such as the National Institute of Health. One notable application of oligonucleotide therapeutics is in the treatment of Hepatic Veno-Occlusive Disease (Hepatic VOD). Biogen, a leading biotech company, has made strides in this area with its approved drug, Spinraza, which utilizes oligonucleotide technology. This focus on research and innovation is expected to fuel the expansion of the market in North America.

Buy Full Report Now

Key Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Agilent Technologies Inc. - The company offers oligonucleotide therapeutics or drugs through its platform called Agilent synthetic oligonucleotides digital analysis platform, namely antisense oligonucleotides ASOs and Small interfering RNA (siRNA)

Agilent Technologies Inc., Alnylam Pharmaceuticals Inc., Biogen Inc., CSL Ltd., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Maravai LifeSciences Holdings Inc., Merck KGaA, Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Market Dynamics and Customer Landscape

The market encompasses various applications in the biomedical science field, including the treatment of Infectious Diseases and Oncology. Key technologies driving this market are Antisense, Ribozymes, Aptamers, miRNA, and RNAi. These therapeutic approaches target specific genes and biological processes to detect minor antibodies and address Disorders. Antisense oligonucleotides (ASOs) and microRNA (miRNA) are essential components of this market. ASOs work by interfering with gene expression, while miRNAs act as RNA targets to regulate gene activity. CpG/Immunostimulatory RNAs are another significant segment, stimulating the immune system to combat diseases.

The Oligonucleotide Therapeutics Market is expanding due to the growing importance of Precision medicine and the increasing healthcare expenditure. The market's growth is further fueled by advancements in Biological processes and the development of new Nucleotides-based therapeutics. In summary, the market is a dynamic and evolving sector in the healthcare industry, with a significant impact on the treatment of various Disorders, particularly in the areas of Infectious Diseases and Oncology. Our researchers analyzed the market research and growth data with 2023  as the base year, along with the key market growth analysis, trends, and challenges. A holistic analysis of drivers, trends, and challenges will help companies refine their marketing strategies to gain a competitive advantage. 

Key Drivers

Increasing incidence of cancer boosts demand for novel diagnostics is notably driving the market growth. The global market for Oligonucleotide Therapeutics, which includes Antisense, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory, RNAi, and other RNA-based therapeutic techniques, is experiencing significant growth due to the increasing prevalence of infectious diseases, prevalence of chronic diseases such as cancer, cardiovascular diseases, neurodegenerative disorders, and kidney diseases. According to recent data, Europe has seen a 2.3% increase in new cancer cases and a 2.4% increase in cancer deaths in 2022. Oligonucleotide Therapeutics offer novel approaches to address these disorders by targeting specific genes and biological processes. For instance, Antisense RNA and miRNA can be used to modulate gene expression, while RNAi treatments can silence specific genes. RNA vaccines are also gaining popularity in the fight against infectious diseases. Pharmaceutical firms are investing heavily in this area of research, driven by healthcare reforms and increasing healthcare expenditure.

Moreover, precision medicine, which relies on genetic testing and personalized treatments, is also fueling the growth of the Oligonucleotide Therapeutics market. Technological advancements, such as CRISPR-Cas9 and RNA vaccines, are further expanding the potential applications of Oligonucleotide Therapeutics in areas like oncology, neurodegenerative disorders, and infectious diseases. However, the high cost of development and production remains a significant challenge for the industry. In summary, the growing need for effective treatments for chronic diseases, coupled with advancements in biomedical science and technology, is driving the growth of the Oligonucleotide Therapeutics market. The market includes various types of nucleotide-based medications, such as Antisense RNA, miRNA, and RNAi treatments, and is used to target various disorders, including cancer, cardiovascular diseases, neurodegenerative disorders, and kidney diseases. Such factors are expected to drive the market growth during the forecast period. 

Significant Trends

Advances in DNA sequencing and increasing adoption of microfluidic techniques is an emerging trend shaping market growth. In the realm of biomedical science, the market for oligonucleotide therapeutics has gained significant traction. This sector encompasses various RNA-based therapeutic techniques, including antisense, ribozymes, aptamers, miRNA, CpG/Immunostimulatory, RNAi, and CRISPR-Cas9. These technologies offer novel approaches to address a range of disorders, such as infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, and kidney diseases. Antisense RNA, miRNA, and RNAi treatments specifically target genes and their expression, providing precision medicine solutions. Pharmaceutical firms are increasingly investing in RNA-based therapeutics, driven by healthcare reforms and rising healthcare expenditure. Advancements in technology, like NGS, have enabled the detection of minor antibodies and the study of biological processes at a molecular level.

Moreover, techniques such as aptamers and RNA vaccines are being explored for their potential in treating neuromuscular diseases, cancer, and other disorders. Nucleotides, the building blocks of DNA and RNA, are the foundation of these medications. Pharmaceutical research in this area continues to grow, with a focus on developing new RNA-based therapies and expanding the application of existing ones. In summary, the oligonucleotide therapeutics market is a dynamic and evolving field, driven by advances in biotechnology, genetic testing, and pharmaceutical research. These innovations hold the potential to revolutionize the diagnosis and treatment of various disorders, including infectious diseases, oncology, neurodegenerative disorders, cardiovascular diseases, and kidney diseases. Such factors are expected to drive the market growth during the forecast period. 

Major Challenges

Inherent issues associated with oligonucleotide therapies is a significant challenge hindering market growth. Oligonucleotide therapeutics, including Antisense, Ribozymes, Aptamers, miRNA, CpG/Immunostimulatory, RNAi, hold great promise in the healthcare industry for addressing various Disorders related to Infectious Diseases, Oncology, Neurodegenerative Disorders, Cardiovascular Diseases, and Kidney Diseases. These RNA-based therapeutic techniques can detect minor antibodies and modulate Gene expression by targeting specific RNA sequences. However, challenges persist in translating these advancements from Biomedical science into commercialized Medications. Delivery of Antisense RNA, miRNA, and RNAi molecules to the desired site remains a significant hurdle.

Additionally, applications of oligonucleotide therapeutics extend to RNA vaccines and CRISPR-Cas9 gene editing. Pharmaceutical firms are actively engaged in Pharmaceutical research to develop these Nucleotide-based treatments for various Disorders. Precision medicine and Gene expression modulation through RNA targets are key areas of focus in Biotechnology and Genetic testing. RNA-based therapeutics, such as RNAi treatments, are poised to revolutionize healthcare expenditure and improve life line curves for numerous Disorders. Neuromuscular diseases and Cancer are potential areas of application for these innovative RNA-based techniques.

Buy Now Full Report

Key Market Customer Landscape

The market report includes the adoption lifecycle of the market growth and forecasting, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

 Customer Landscape

Segment Overview

The market research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in "USD Million" for the period 2024-2028, as well as historical data from 2018-2022 for the following segments.

• Type Outlook
  • Antisense oligonucleotides
  • RNA interference
  • Aptamers and others

• Application Outlook
  • Neurological
  • Cancer
  • Infectious diseases and others

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina 
    • Australia 

Market Analyst Overview

The market is a significant sector in the healthcare industry, driven by the increasing demand for personalized medicines and gene therapies. Oligonucleotides are short sequences of DNA or RNA used for therapeutic purposes, including antisense therapy, RNA interference, and gene therapy. The market is anticipated to grow due to the increasing number of applications in various therapeutic areas such as neurology, oncology, and cardiology. Advancements in technology, including the development of new delivery systems and synthetic methods, are also contributing to the market growth. The market is segmented based on type, application, and region. Antisense oligonucleotides and RNA interference oligonucleotides are the major types of oligonucleotide therapeutics. Neurology, oncology, and cardiology are the major applications. The market is expected to grow at a steady pace in the coming years due to the increasing demand for personalized medicines and the development of new technologies.

Additionally, the market is competitive, with key players including Alnylam Pharmaceuticals, Ionis Pharmaceuticals, and Sarepta Therapeutics. These companies are investing in research and development to expand their product portfolios and gain a competitive edge. The market is also witnessing collaborations and partnerships between companies to accelerate the development of new therapies. In conclusion, the market is a growing sector in the healthcare industry, driven by the increasing demand for personalized medicines and advancements in technology. The market is expected to grow steadily in the coming years due to the increasing number of applications in various therapeutic areas and the development of new technologies. The market is competitive, with key players investing in research and development to expand their product portfolios and gain a competitive edge.

Market Scope
Report Coverage	Details
Page number	169
Base year	2023
Historic period	2018 - 2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 19.87%
Market Growth 2024-2028	USD 13.44 billion
Market structure	Fragmented
YoY growth 2023-2024(%)	17.98
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 39%
Key countries	US, Canada, UK, Germany, and Japan
Competitive landscape	Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks
Key companies profiled	Agilent Technologies Inc., Alnylam Pharmaceuticals Inc., Biogen Inc., CSL Ltd., GlaxoSmithKline Plc, Ionis Pharmaceuticals Inc., Maravai LifeSciences Holdings Inc., Merck KGaA, Nippon Shinyaku Co. Ltd., Novartis AG, Pfizer Inc., Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc.
Market dynamics	Parent market analysis, Market forecasting, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the market forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the between 2024 and 2028
• Precise estimation of the size and its contribution to the market in focus on the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies' position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch